Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jul 27, 2024; 16(7): 973-979
Published online Jul 27, 2024. doi: 10.4254/wjh.v16.i7.973
Roles of transforming growth factor-β signaling in liver disease
Xiao-Ling Wang, Meng Yang, Ying Wang
Xiao-Ling Wang, Meng Yang, Ying Wang, Clinical Laboratory, Shanxi Academy of Traditional Chinese Medicine, Taiyuan 030012, Shanxi Province, China
Author contributions: All authors participated in the discussion of the content of the article; The manuscript was written by Wang XL, Yang M and Wang Y; and all authors reviewed and edited the manuscript prior to submission.
Supported by Shanxi Provincial Health Commission Youth Research Project, No. 2021081; and Traditional Chinese Medicine Administration of Shanxi Province, No. 2023ZYYDA2001.
Conflict-of-interest statement: The authors declare having no conflict of interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Ling Wang, PhD, Chief Technician, Clinical Laboratory, Shanxi Academy of Traditional Chinese Medicine, No. 46 Bingzhou West Street, Yingze District, Taiyuan 030012, Shanxi Province, China. wangxiaoling24@163.com
Received: December 28, 2023
Revised: March 4, 2024
Accepted: May 24, 2024
Published online: July 27, 2024
Processing time: 211 Days and 0 Hours
Core Tip

Core Tip: Transforming growth factor-β (TGF-β) participates in diverse signaling pathways and exhibits contradictory roles in liver immunity, inflammation, repair, fibrosis, and other biological processes. In this editorial, we review the evidence for potential TGF-β signaling pathway molecules as diagnostic or therapeutic targets for different liver disease stages.